Functional Tests

IBS-smart

Overview

This test is recommended for patients with IBS-D/M related gastrointestinal symptoms such as:

  • Diarrhea or alternating diarrhea and constipation
  • Stomach pain
  • Bloating

Food poisoning is the leading known cause of IBS (60-70% of cases of IBS with diarrhea).


Indications

This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

(Nordic Laboratories accept no cost or claims related to any phlebotomy services in the event of sample rejection or failure for any reason. By ordering this, or any test, requiring phlebotomy services, you accept any inherent risk and any associated costs.)

IBS Smart is an ELISA blood test that measures the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome (IBS).

The two validated IBS biomarkers, anti-CdtB and anti-vinculin, are elevated in a majority of IBS patients with diarrheal symptoms and can diagnose diarrhea-predominant or mixed-type IBS (IBS-D or IBS-M). Anti-CdtB and anti-vinculin are not commonly elevated in patients with constipation-predominant IBS (IBS-C).

This test offers physicians an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D and IBS-M), thereby preventing any unnecessary invasive procedures and set a faster path to targeted treatment.

If the patient's IBS Smart results are POSITIVE, the patient has clinical IBS 96-100% of the time.

Practical

This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

(Nordic Laboratories accept no cost or claims related to any phlebotomy services in the event of sample rejection or failure for any reason. By ordering this, or any test, requiring phlebotomy services, you accept any inherent risk and any associated costs.)

Sample Requirements:

Blood drawn (Lavender top K2 EDTA tube).

Plasma extracted and FROZEN.

Minimum 200 µL plasma.


Average processing time:

10-12 days

Downloads

Research

Morales, W., Rezaie, A., Barlow, G. et al. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig Dis Sci 64, 3115–3121 (2019). https://doi.org/10.1007/s10620-019-05684-6

Lacy, Brian E. PhD, MD, FACG1; Pimentel, Mark MD, FACG2; Brenner, Darren M. MD, FACG3; Chey, William D. MD, FACG4; Keefer, Laurie A. PhD5; Long, Millie D. MDMPH, FACG (GRADE Methodologist)6; Moshiree, Baha MD, MSc, FACG7. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. The American Journal of Gastroenterology 116(1):p 17-44, January 2021. | DOI: 10.14309/ajg.0000000000001036